TY - JOUR
T1 - Chemical derivatization of therapeutic proteins
AU - Smith, Richard A.G.
AU - Dewdney, Janet M.
AU - Fears, Robin
AU - Poste, George
PY - 1993/9
Y1 - 1993/9
N2 - Despite major advances in redesigning and producing proteins through recombinant DNA technology, many therapeutic proteins are still produced by extraction from biological tissues or fluids, or from nonrecombinant microorganisms. Modification of such proteins, to improve potency and bioavailability and reduce immunogenicity, can only be carried out post-translationally by chemical-derivatization methods. Genetic- and chemical-modification methods are not mutually exclusive, however, and may be combined to optimize protein-engineering strategies, because chemical modification can introduce structural changes that are not encoded by DNA into both recombinant, and nonrecombinant proteins.
AB - Despite major advances in redesigning and producing proteins through recombinant DNA technology, many therapeutic proteins are still produced by extraction from biological tissues or fluids, or from nonrecombinant microorganisms. Modification of such proteins, to improve potency and bioavailability and reduce immunogenicity, can only be carried out post-translationally by chemical-derivatization methods. Genetic- and chemical-modification methods are not mutually exclusive, however, and may be combined to optimize protein-engineering strategies, because chemical modification can introduce structural changes that are not encoded by DNA into both recombinant, and nonrecombinant proteins.
UR - http://www.scopus.com/inward/record.url?scp=0027656447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027656447&partnerID=8YFLogxK
U2 - 10.1016/0167-7799(93)90100-N
DO - 10.1016/0167-7799(93)90100-N
M3 - Review article
C2 - 7764087
AN - SCOPUS:0027656447
SN - 0167-7799
VL - 11
SP - 397
EP - 403
JO - Trends in Biotechnology
JF - Trends in Biotechnology
IS - 9
ER -